Literature DB >> 17641205

CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.

Sung W Choi1, Gerhard C Hildebrandt, Krystyna M Olkiewicz, David A Hanauer, Meghana N Chaudhary, Ines A Silva, Clare E Rogers, Daphne T Deurloo, Jacki M Fisher, Chen Liu, David Adams, Stephen W Chensue, Kenneth R Cooke.   

Abstract

Acute graft-versus-host disease (GVHD) and leukemic relapse are serious complications of allogeneic stem-cell transplantation (SCT). Recruitment of activated T cells to host target tissues or sites of leukemic infiltration (graft-versus-leukemia [GVL]) is likely mediated by chemokine receptor-ligand interactions. We examined the contribution of donor cell CCR1 expression to the development of GVHD and GVL using a well-established murine SCT model (B6 --> B6D2F1) and CCR1-deficient mice (CCR1(-/-)). Allo-SCT with CCR1(-/-) donor cells significantly reduced systemic and target organ GVHD severity, and CCR1 expression on both T cells and accessory cells contributed to GVHD mortality. Significant GVL activity was preserved following CCR1(-/-) SCT, but the survival advantage diminished with increasing tumor burden. We then explored the effects of CCR1 expression on allo-specific T-cell responses. Although cytolytic effector function was maintained on a per-cell basis, T-cell proliferation and IFNgamma secretion were significantly reduced both in vivo and in vitro. T-cell function was partially dependent on interactions between CCR1 and CCL5. Collectively, these data demonstrate that CCR1 expression on donor cells contributes to the development of both GVHD and GVL, and suggest that CCR1/CCL5 receptor-ligand interactions modulate allo-specific T-cell responses occurring in this context.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641205      PMCID: PMC2200916          DOI: 10.1182/blood-2007-05-087403

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  RANTES is produced by CD8+ T cells during acute rejection of skin grafts.

Authors:  S Koga; A Kapoor; A C Novick; H Toma; R L Fairchild
Journal:  Transplant Proc       Date:  2000-06       Impact factor: 1.066

3.  Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment.

Authors:  H J Gröne; C Weber; K S Weber; E F Gröne; T Rabelink; C M Klier; T N Wells; A E Proudfood; D Schlöndorff; P J Nelson
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

4.  Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.

Authors:  A E Proudfoot; R Buser; F Borlat; S Alouani; D Soler; R E Offord; J M Schröder; C A Power; T N Wells
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.

Authors:  W Gao; P S Topham; J A King; S T Smiley; V Csizmadia; B Lu; C J Gerard; W W Hancock
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 6.  Pathophysiologic mechanisms of acute graft-vs.-host disease.

Authors:  J L Ferrara; R Levy; N J Chao
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

Review 7.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

8.  IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Authors:  T Teshima; G R Hill; L Pan; Y S Brinson; M R van den Brink; K R Cooke; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

9.  CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts.

Authors:  S Koga; A C Novick; H Toma; R L Fairchild
Journal:  Transplantation       Date:  1999-03-27       Impact factor: 4.939

10.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

Authors:  W D Shlomchik; M S Couzens; C B Tang; J McNiff; M E Robert; J Liu; M J Shlomchik; S G Emerson
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

View more
  36 in total

1.  The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis.

Authors:  Michael W Milks; James G Cripps; Heping Lin; Jing Wang; Richard T Robinson; Jennifer L Sargent; Michael L Whitfield; James D Gorham
Journal:  Liver Int       Date:  2009-04-16       Impact factor: 5.828

2.  The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.

Authors:  Senthilnathan Palaniyandi; Reena Kumari; Sabarinath Venniyil Radhakrishnan; Ethan Strattan; Natalya Hakim; Reinhold Munker; Melissa V Kesler; Gerhard C Hildebrandt
Journal:  Transplantation       Date:  2020-12       Impact factor: 4.939

3.  Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Authors:  Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  J Antimicrob Chemother       Date:  2015-04-16       Impact factor: 5.790

Review 4.  Current and emerging strategies for the prevention of graft-versus-host disease.

Authors:  Sung Won Choi; Pavan Reddy
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

5.  Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy.

Authors:  Lili Xie; Yuqin Yin; Larry Benowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

6.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

7.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

8.  Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Authors:  Yvonne A Efebera; Susan Geyer; Leslie Andritsos; Sumithira Vasu; Samantha Jaglowski; Anissa Bingman; William Blum; Rebecca Klisovic; Craig C Hofmeister; Don M Benson; Sam Penza; Patrick Elder; Katie Cortright; Rhonda Kitzler; Kevin Coombes; Lynn O'Donnell; Beth Daneault; Hillary Bradbury; Jianying Zhang; Xilin Chen; Sabrina Garman; Parvathi Ranganathan; Xueyan Yu; Jessica Hofstetter; Jianhua Yu; Ramiro Garzon; Scott R Scrape; Gerard Lozanski; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-06       Impact factor: 5.742

9.  Efficacy of azithromycin in preventing lethal graft-versus-host disease.

Authors:  S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.